0R34 Stock Chart & Stats
$267.74
-$2.35(-0.88%)
At close: 4:00 PM EDT
$267.74
-$2.35(-0.88%)
Day’s Range― - ―
52-Week Range$184.47 - $281.20
Previous CloseN/A
Volume13.80K
Average Volume (3M)7.38K
Market Cap
$621.22B
Enterprise Value$691.53B
Total Cash (Recent Filing)$17.23B
Total Debt (Recent Filing)$44.65B
Price to Earnings (P/E)39.1
Beta0.62
Next Earnings
Jan 26, 2027EPS Estimate
2.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.60
Shares Outstanding2,409,898,700
10 Day Avg. Volume9,750
30 Day Avg. Volume7,378
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue6.96
Enterprise Value/Gross Profit10.12
Enterprise Value/Ebitda22.45
Forecast
1Y Price Target
$288.71Price Target Upside7.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)11.11
Revenue Forecast (FY)$101.21B
Bulls Say, Bears Say
Bulls Say
Innovative Medicine GrowthStrong growth across oncology, immunology, neuroscience, and other therapeutic areas indicates broad product adoption rather than dependence on a single medicine. Multiple expanding brands can sustain revenue momentum, support reinvestment, and help offset future product-level erosion.
Reliable Cash GenerationConsistently positive operating and free cash flow gives Johnson & Johnson substantial capacity to fund research, business development, dividends, and debt service internally. This recurring cash engine strengthens resilience and supports continued investment through changing healthcare cycles.
Innovation And Portfolio ExpansionInvestment in next-generation oncology platforms expands the pipeline beyond current products and targets difficult-to-treat cancers with significant unmet need. Although costly initially, these capabilities can reinforce Johnson & Johnson’s long-term competitive position and future growth options.
Bears Say
Margin PressureThe decline in adjusted margins shows that product mix, amortization, research spending, and transaction costs are currently absorbing part of the company’s operating leverage. Persistent pressure would reduce the amount of revenue growth converting into earnings and cash.
Higher Debt And Slower Free Cash FlowHigher debt alongside weaker recent free-cash-flow growth reduces financial flexibility compared with prior lower-leverage periods. The balance sheet remains generally sound, but less conservative coverage can constrain capital allocation and increase sensitivity to execution or transaction costs.
Biosimilar ErosionSTELARA’s decline demonstrates how biosimilar competition can erode established pharmaceutical revenue after exclusivity weakens. Continued pressure on mature franchises could offset newer-product growth, requiring sustained pipeline productivity and commercial execution to preserve overall expansion.
Johnson & Johnson News
0R34 FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest share price was $184.47 and its highest was $281.20 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $621.22B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jan 26, 2027 which is in 95 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 13, 2026. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.522 by $0.068.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.9.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,898,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.59 in its last earnings report, beating expectations of $2.522. Following the earnings report the stock price went down -5.87%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in GB:0R34
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$288.71 (7.83% Upside)
$288.71 (7.83% Upside)
Blogger Sentiment
Bullish
GB:0R34 Sentiment 73%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $67.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.82%
12-Months-Change
Fundamentals
Return on Equity
19.55%
Trailing 12-Months
Asset Growth
2.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
0R34 Company Deck
0R34 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Johnson & Johnson reported 6% operational sales growth, strong momentum in Innovative Medicine, significant growth from key oncology, immunology, and neuroscience brands, progress in MedTech innovation, strong cash generation, and raised 2026 guidance. These positives were partly offset by a MedTech performance shortfall, declines in Abiomed, surgery, and STELARA, lower adjusted EPS and margins, and substantial talc litigation and transaction-related charges. Management nevertheless expressed confidence in improving MedTech performance, finishing 2026 strongly, and achieving double-digit growth by the end of the decade.View all GB:0R34 earnings summaries0R34 Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
0R34 Stock 12 Month Forecast
Average Price Target
$288.71
▲(7.83% Upside)